View Older Stories View More Recent Stories
-
Amgen (AMGN) Declares $2.38 Quarterly Dividend; 3.2% Yield
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Amgen (AMGN) PT Raised to $261 at BofA Securities
-
Amgen (AMGN) PT Raised to $305 at Citi
-
Amgen (AMGN) PT Raised to $326 at UBS
-
U.S. large biotech stocks Q2 earnings preview
-
Amgen (AMGN) PT Lowered to $335 at BMO Capital
-
Piper Sandler on Amgen (AMGN): 'Another Clinical Win For The Oncology Franchise'
-
William Blair Reiterates Outperform Rating on Amgen (AMGN)
-
Amgen (AMGN) Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (Fgfr2B) Positive First-line Gastric Cancer
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
-
Truist Securities Reiterates Hold Rating on Amgen (AMGN)
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Amgen (AMGN) reports full results from Part 1 of the Phase 2 study of MariTide
-
Jefferies Downgrades Vigil Neuroscience Inc (VIGL) to Hold
-
Amgen (AMGN) PT Trimmed to $328 at Piper Sandler
-
Regeneron (REGN) Prevails over Amgen (AMGN) in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
-
Popular stocks volume: AMGN GILD JNJ LLY MRK PFE SNY AZN GSK NVS BMY NVO CVS CI UNH CAH MCK COR W RH
-
Erste Group Downgrades Amgen (AMGN) to Hold
-
Amgen (AMGN) option IV flat
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Stocks expected to have increasing option volume: SYK AMGN FIVN CART TWLO BMRN PCTY JNPR WEN CI CYTK TWLO
-
Amgen (AMGN) Tops Q1 EPS by 61c; offers guidance
-
Amgen (AMGN) call put ratio 3.3 calls to 1 put into quarter results
-
Amgen (AMGN) confirms $900M Ohio manufacturing expansion
-
Amgen (AMGN) Announces $900 Million Expansion Of Ohio Drugmaking Plant - Bloomberg
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Cantor Fitzgerald Assumes Amgen (AMGN) at Neutral
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $319 at UBS
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Amgen (AMGN): Imdelltra Demonstrated Superior Overall Survival In Small Cell Lung Cancer
-
Pharma stocks slide after Trump signals tariffs on sector
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Citi Reiterates Neutral Rating on Amgen (AMGN)
-
Amgen (AMGN): Uplizna Is Now The First And Only Fda-approved Treatment For Igg4-related Disease
-
FDA Approves Amgen's (AMGN) Uplizna for Treatment of Immunoglobulin G4-Related Disease in Adult Patients - Website
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Weighing in on obesity: Catalyst-rich 2025 ahead in a growing competitive landscape
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Piper Sandler on Amgen (AMGN): 'Repatha Remains a Standout'
-
Cantor Fitzgerald says more options, newer targets will expand obesity market
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Amgen (AMGN) Reports New UPLIZNA Data
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN) as 'ROCA PH3 Horizon Shows Improved Safety'
-
Amgen (AMGN) Starts Late-stage Studies Of Monthly Obesity Drug - Bloomberg, Citing Comments at Conf.

